Immix Biopharma, Inc.
جودة البيانات: 100%
IMMX
Nasdaq
Manufacturing
Chemicals
KWD 9.26
▼
KWD 0.49
(-5.03%)
القيمة السوقية: 511.30 M
السعر
KWD 9.65
القيمة السوقية
511.30 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -24.66 M
Capital efficient — spends only 3.66% of revenue on capex
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-455.78%
أقل من متوسط القطاع (-53.53%)
ROIC-318.61%
Net Margin-147.19%
Op. Margin-149.78%
الأمان
Debt / Equity
N/A
Current Ratio1.53
Interest CoverageN/A
التقييم
PE (TTM)
-17.37
أقل من متوسط القطاع (-1.48)
P/B Ratio61.86
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -17.4 | -1.5 |
| P/B | 61.9 | 1.6 |
| ROE % | -455.8 | -53.5 |
| Net Margin % | -147.2 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
5 محللين
Strong Buy
الحالي
KWD 9.26
المستهدف
KWD 17.56
KWD 14.80
KWD 15.00
KWD 23.00
التوقعات
مكرر الربحية المستقبلي
-12.73
ربحية السهم المستقبلية
-KWD 0.73
الإيرادات المقدّرة
56.42 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 0.73
-KWD 1.48 – -KWD 0.07
|
56.42 M | 4 |
| FY2026 |
-KWD 0.77
-KWD 0.96 – -KWD 0.53
|
0.0 | 5 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.21
-KWD 0.23 – -KWD 0.18
|
0.0 | 4 |
| 2026 Q1 |
-KWD 0.21
-KWD 0.25 – -KWD 0.17
|
0.0 | 4 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.16 | -KWD 0.28 | -75.0% |
| Q32025 | -KWD 0.19 | -KWD 0.24 | -26.3% |
| Q22025 | -KWD 0.16 | -KWD 0.22 | -37.5% |
| Q12025 | -KWD 0.23 | -KWD 0.15 | +34.8% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0.00% | Revenue Growth (3Y) | 0.00% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 20.00 M | Net Income (TTM) | -29.44 M |
| ROE | -455.78% | ROA | -164.85% |
| Gross Margin | N/A | Operating Margin | -149.78% |
| Net Margin | -147.19% | Free Cash Flow (TTM) | -24.66 M |
| ROIC | -318.61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.53 |
| Interest Coverage | N/A | Asset Turnover | 1.12 |
| Working Capital | 5.73 M | Tangible Book Value | 8.26 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -17.37 | Forward P/E | N/A |
| P/B Ratio | 61.86 | P/S Ratio | 25.57 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -4.82% | ||
| Market Cap | 511.30 M | Enterprise Value | 495.35 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.89 | Revenue / Share | 0.38 |
| FCF / Share | -0.47 | OCF / Share | -0.45 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 3.66% | FCF Conversion | 83.78% |
| SBC-Adj. FCF | -27.27 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 20.00 M | 20.00 M | 20.00 M | — | — |
| Net Income | -29.44 M | -21.61 M | -15.43 M | -8.23 M | -24.38 M |
| EPS (Diluted) | -0.89 | -0.76 | -0.89 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -29.96 M | -22.67 M | -16.14 M | -8.22 M | -1.35 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 16.26 M | 11.29 M | 8.74 M | 4.20 M | 126,527.0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 497.0 | 497.0 | 179,853.0 |
| Income Tax | 37,724.0 | 41,037.0 | 26,415.0 | 10,268.0 | 6,013.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 104.84 M | 22.95 M | 19.93 M | 14.91 M | 18.19 M |
| Total Liabilities | 11.04 M | 9.70 M | 3.72 M | 1.75 M | 202,039.0 |
| Shareholders' Equity | 93.80 M | 13.25 M | 16.41 M | 13.16 M | 17.99 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 93.93 M | 17.68 M | 17.51 M | 13.44 M | 17.64 M |
| Current Assets | 101.24 M | 20.20 M | 19.79 M | 14.90 M | 18.19 M |
| Current Liabilities | 10.11 M | 8.69 M | 3.72 M | 1.27 M | 202,039.0 |
{"event":"ticker_viewed","properties":{"ticker":"IMMX","listing_kind":"stock","pathname":"/stocks/immx","exchange":"Nasdaq","country":"US"}}